Biotech Stock News (ARWR)(AMGN)(ATHX)(PFE)

Arrowhead Research Corp (NASDAQ:ARWR) On April 13, 2015 Arrowhead announced that it was given the go-ahead by the FDA to begin treating patients in the phase 2b Hepatitis B study. ┬áThe drug compound being used in the study is known as ARC-520 which is an RNAi drug. RNAi stands for RNA interference and these types … Read more

Arrowhead Research Stock Falls On Jeffries Downgrade

Arrowhead Research Corp (NASDAQ: ARWR) Yesterday was a great day for ARWR investors. After announcing that the company received clearance from the FDA to move forward with testing of a treatment, the stock gained nearly 3%. Unfortunately, the tides have changed for Arrowhead Research stock today. After an analysts at Jeffries downgraded the stock, we’ve … Read more

Arrowhead Research Stock Climbs On FDA Clearance

Arrowhead Research Corp (NASDAQ: ARWR) Arrowhead Research Corp stock spiked strongly this morning following clearance from the FDA. The clearance provided from the United States Food and Drug Administration gives Arrowhead Research the OK to move forward with Phase 2b testing of ARC-520. The drug is a candidate for the treatment of chronic hepatitis B … Read more